Policy | December 16, 2025
Pharma overhaul: EMA hails “Once-in-a-Generation” reform
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The companies aim to expand treatment options for millions living with metabolic disorders
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Expands bioprocessing footprint across Asia
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
While Merck can appeal, Halozyme said it expects the order to hold
Subscribe To Our Newsletter & Stay Updated
